| Drug Type Antibody fusion proteins | 
| Synonyms- | 
| Target | 
| Action agonists, inhibitors | 
| Mechanism IL-2R agonists(Interleukin-2 receptor agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | South Korea  | 30 Apr 2025 | 






